Geneesmiddelen | Horizonscan geneesmiddelen

Andexanet alfa Apixaban ^G Ravulizumab ^IND

Emicizumab ^IND Entranacogene dezaparvovec Eptacog beta (activated) Fibrinogen Fidanacogene elaparvovec Turoctocog alfa pegol Valoctocogene roxaparvovec

Alirocumab ^IND Bempedoic acid Bempedoic acid / ezetimibe Inclisiran Volanesorsen

Allogenic immunomodulatory progenitor cells Angiotensin II Apabetalon Dapagliflozine ^IND

Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). ^IND Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) ^IND

Icosapent ethyl PLX-PAD Regadenoson ^IND Tafamidis ^IND

Treprostinil Udenafil

Entresto is indicated in adult patients for treatment of symptomatic chronic heart failure with ejection fraction below 55/60% ^IND Post acute Myocardial Infarction ^IND

Vericiguat

Avatrombopag Crizanlizumab Daprodustat

Paroxysmal nocturnal haemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) ^BS Paroxysmal nocturnal haemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) ^BS Paroxysmal nocturnal haemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). ^BS

Ferumoxytol Hydroxycarbamide ^G Luspatercept Mepolizumab ^IND Ravulizumab Roxadustat Thrombomodulin alfa Vadadustat Voxelotor

Informatie over geneesmiddelen die in de nabije toekomst op de markt verwacht worden.